Patents by Inventor Rolf W. Hartmann
Rolf W. Hartmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11883387Abstract: The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.Type: GrantFiled: July 3, 2019Date of Patent: January 30, 2024Assignee: Helmholtz-Zentrum Für Infektionsforschung GmbHInventors: Ahmed S. A. Ahmed, Martin Empting, Mostafa Hamed, Rolf W. Hartmann, Jörg Haupenthal, Thomas Hesterkamp, Ahmed A. M. Kamal, Christine K. Maurer, Teresa Röhrig, Christian Schütz, Samir Yahiaoui, Michael Zender
-
Publication number: 20230321123Abstract: The present invention relates to compounds of formula (Ia) and the use thereof as inhibitors of P. aeruginosa virulence factor LasB. Formula (Ia). These compounds are useful in the treatment of bacterial infections, especially caused by P. aeruginosa.Type: ApplicationFiled: August 24, 2021Publication date: October 12, 2023Inventors: Christian Ducho, Rolf W. Hartmann, Jörg Haupenthal, Anna K. H. Hirsch, Andreas Kany, Cansu Kaya, Jelena Konstantinovic, Katrin Voos, Isabell Walter, Samir Yahiaoui, Ahmed Saad Abdelsamine, Christian Schütz, Ravindra Jumde, Alexander Kiefer
-
Publication number: 20230286942Abstract: The present invention relates to a compounds according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonasaeruginosa or Burkholderia infection.Type: ApplicationFiled: December 30, 2020Publication date: September 14, 2023Inventors: Christian Schütz, Martin Empting, Ahmed S. Ahmed, Mostafa Hamed, Rolf W. Hartmann, Teresa Röhrig, Andreas M. Kany, Anna K. Hirsch
-
Publication number: 20230146507Abstract: The present invention related to novel inhibitors of metallo-?3-lactamases of formula (I) wherein R1 is an optionally substituted aryl group of an optionally substituted heteroaryl group, and the use thereof in the treatment of bacterial infections, especially in combination with ?-lactam antibiotics.Type: ApplicationFiled: March 23, 2021Publication date: May 11, 2023Inventors: Rolf W. Hartmann, Jelena Konstantinovic, Jörg Haupenthal, Anna K. Hirsch, Andreas M. Kany, Cansu Kaya, Samir Yahiaoui, Thomas Wichelhaus, Eugen Proschak
-
Publication number: 20230106506Abstract: The present invention relates to a compound according to general formula (I), which acts as an inverse agonist of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS), sometimes also referred to as MvfR); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.Type: ApplicationFiled: December 30, 2020Publication date: April 6, 2023Inventors: Mostafa Hamed, Ahmed S. Ahmed, Martin Empting, Christian Schütz, Rolf W. Hartmann, Teresa Röhrig, Andreas M. Kany, Anna K. Hirsch
-
Patent number: 11225503Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.Type: GrantFiled: June 10, 2020Date of Patent: January 18, 2022Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBHInventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Huettel
-
Publication number: 20210353606Abstract: The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.Type: ApplicationFiled: July 3, 2019Publication date: November 18, 2021Inventors: Ahmed S.A. Ahmed, Martin Empting, Mostafa Hamed, Rolf W. Hartmann, Jörg Haupenthal, Thomas Hesterkamp, Ahmed A.M. Kamal, Christine K. Maurer, Teresa Röhrig, Christian Schütz, Samir Yahiaoui, Michael Zender
-
Publication number: 20200331964Abstract: The present invention provides cystobactamides of formula (I): R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2 and the use thereof for the treatment or prophylaxis of bacterial infections.Type: ApplicationFiled: June 10, 2020Publication date: October 22, 2020Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Huettel
-
Patent number: 10793600Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.Type: GrantFiled: July 23, 2018Date of Patent: October 6, 2020Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBHInventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
-
Patent number: 10472326Abstract: The present invention relates to compounds according to general formula (I); to pharmaceutical compositions comprising one or more of the compound(s); and to the use of the compound(s) as anti-infectives.Type: GrantFiled: April 3, 2014Date of Patent: November 12, 2019Assignee: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBHInventors: Cenbin Lu, Christine K. Maurer, Benjamin Kirsch, Anke Steinbach, Rolf W. Hartmann, Mathias Müsken, Susanne Häussler
-
Publication number: 20190185514Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections: R1—Ar1-L1-Ar2-L2-Ar3-L3-Ar4-L4-Ar5—R2??(I):Type: ApplicationFiled: July 23, 2018Publication date: June 20, 2019Inventors: Sascha Baumann, Jennifer Herrmann, Kathrin Mohr, Heinrich Steinmetz, Klaus Gerth, Ritesh Raju, Rolf Müller, Rolf W. Hartmann, Mostafa Hamed, Walid A. M. Elgaher, Maria Moreno, Franziska Gille, Liang Liang Wang, Andreas Kirschning, Stephan Hüttel
-
Publication number: 20180228858Abstract: A plant extract, derived from a Salvia spp, may include one of at least one tanshinone compound, or at least one tanshinone compounds including a CYP11B1 inhibitory amount of at least one of tanshinone I and dihydrotanshinone. The plant extract may be used for use in the treatment of a wound or Cushing's syndrome.Type: ApplicationFiled: November 30, 2015Publication date: August 16, 2018Inventors: Andrew B. Gallagher, Rolf W. Hartmann, Matthias Engel, Axel Koch, Chris J. Van Koppen
-
Publication number: 20170022165Abstract: The present invention relates to compounds according to general formula (I); to pharmaceutical compositions comprising one or more of the compound(s); and to the use of the compound(s) as anti-infectives.Type: ApplicationFiled: April 3, 2014Publication date: January 26, 2017Inventors: Cenbin Lu, Christine K. Maurer, Benjamin Kirsch, Anke Steinbach, Rolf W. Hartmann, Mathias Müsken, Susanne Häussler
-
Patent number: 8685960Abstract: The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 ?-hydroxylase (CYP11 B1).Type: GrantFiled: May 5, 2009Date of Patent: April 1, 2014Assignee: Elexopharm GmbHInventors: Rolf W. Hartmann, Ralf Heim, Simon Lucas
-
Patent number: 8541404Abstract: The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11?-hydroxylase (CYP11B1) with these compounds.Type: GrantFiled: November 3, 2010Date of Patent: September 24, 2013Assignee: ElexoPharm GmbHInventors: Rolf W. Hartmann, Ralf Heim, Simon Lucas
-
Publication number: 20110118241Abstract: The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 ?-hydroxylase (CYP11 B1).Type: ApplicationFiled: May 5, 2009Publication date: May 19, 2011Applicant: Universitat des SaarlandesInventors: Rolf W. Hartmann, Ralf Heim, Simon Lucas
-
Publication number: 20110112067Abstract: The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11?-hydroxylase (CYP11B1) with these compounds.Type: ApplicationFiled: November 3, 2010Publication date: May 12, 2011Applicant: Universitat des SaarlandesInventors: Rolf W. Hartmann, Ralf Heim, Simon Lucas
-
Publication number: 20090221591Abstract: The invention relates to compounds for selectively inhibiting human corticosteroid synthases CYP1 1 B1 and CYP1 1 B2, and to the production and use thereof for treating hypercortisolism, diabetes mellitus, hyperaldosteronism, cardiac insufficiency, myocardial fibrosis, depression, age-related cognitive decline and metabolic syndrome.Type: ApplicationFiled: March 2, 2006Publication date: September 3, 2009Applicant: Universitat Des SaarlandesInventors: Rolf W. Hartmann, Marieke Voets, Ursula Müller-Vieira
-
Patent number: 4839370Abstract: Novel 3-aryl-3-cycloalkyl-piperidine-2,6-dione derivatives of the general formula I: ##STR1## in which A is a 4-aminophenyl radical or a pyridyl-(4)-radical and R.sub.1 is a saturated or unsaturated C.sub.3 -C.sub.10 -cycloalkyl radical or a C.sub.3 -C.sub.12 -alkenyl radical as well as physiologically acceptable salts thereof. The compounds are useful as inhibitors of estrogen biosynthesis. The compounds are made by a process which includes the step of heating a compound of the formula II ##STR2## wherein A and R.sub.1 have the meanings given above, and in addition A may also be a phenyl radical or a 4-nitrophenyl radical, X and Y are the same or different and repesent CN or COOC.sub.1 -C.sub.6 -alkyl and X or Y may also be COOH or a carboxylic acid ester group of the formula COOC.sub.1 -C.sub.6 -alkyl group, in a high boiling solvent at a temperature between 50.degree. and 200.degree. C. in particular between 80.degree. and 100.degree. C.Type: GrantFiled: July 31, 1987Date of Patent: June 13, 1989Assignee: Asta-Pharma AGInventors: Rolf W. Hartmann, Christine Batzl
-
Patent number: 4745233Abstract: Antitumor compounds corresponding to the following formula: ##STR1## in which the substituents R.sub.1 and R.sub.2 may be the same or different and represent hydrogen, an aminocarbonyl group, a C.sub.1 -C.sub.6 alkylaminocarbonyl group, a di-C.sub.1 -C.sub.6 -alkylaminocarbonyl group, the group PO(OH).sub.2, a C.sub.2 -C.sub.8 alkanoyl group, a C.sub.2 -C.sub.8 halogen alkanoyl group or a C.sub.3 -C.sub.8 alkenoyl group, a process for their preparation, and their use in treating oestrogen-receptor-positive-tumors as well as the prostate carcinoma.Type: GrantFiled: June 9, 1986Date of Patent: May 17, 1988Assignee: Asta-Werke AktiengesellschaftInventors: Helmut Schonenberger, Rolf W. Hartmann, Martin Schneider, Walter Schwarz, Jurgen Engel